Activating beige adipocytes in white adipose tissue (WAT) to increase energy expenditure is a promising strategy to combat obesity. We identified that mesencephalic astrocyte–derived neurotrophic factor (Manf) is a feeding-induced hepatokine. Liver-specific Manf overexpression protected mice against high-fat diet–induced obesity and promoted browning of inguinal subcutaneous WAT (iWAT). Manf overexpression in liver was also associated with decreased adipose inflammation and improved insulin sensitivity and hepatic steatosis. Mechanistically, Manf could directly promote browning of white adipocytes via the p38 MAPK pathway. Blockade of p38 MAPK abolished Manf-induced browning. Consistently, liver-specific Manf knockout mice showed impaired iWAT browning and exacerbated diet-induced obesity, insulin resistance, and hepatic steatosis. Recombinant Manf reduced obesity and improved insulin resistance in both diet-induced and genetic obese mouse models. Finally, we showed that circulating Manf level was positively correlated with BMI in humans. This study reveals the crucial role of Manf in regulating thermogenesis in adipose tissue, representing a potential therapeutic target for obesity and related metabolic disorders.
Cyclooxygenase-2 (COX-2)–derived prostaglandins participate in a number of pathophysiological responses such as inflammation, carcinogenesis, and modulation of cell growth and survival. This study used complementary approaches of COX-2 transgenic (Tg) and knockout (KO) mouse models to evaluate the mechanism of COX-2 in Fas-induced hepatocyte apoptosis and liver failure in vivo. We generated Tg mice with targeted expression of COX-2 in the liver by using the albumin promoter-enhancer–driven vector. The COX-2 Tg, COX-2 KO, and wild-type mice were treated with the anti-Fas antibody Jo2 (0.5 μg/g of body weight) for 4 to 6 hours, and the extent of liver injury was assessed by histopathology, serum aminotransferases, TUNEL staining, and caspase activation. The COX-2 Tg mice showed resistance to Fas-induced liver injury in comparison with the wild-type mice; this was reflected by the lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, less liver damage, and less hepatocyte apoptosis (P < 0.01). In contrast, the COX-2 KO mice showed significantly higher serum ALT and AST levels, more prominent hepatocyte apoptosis, and higher levels of caspase-8, caspase-9, and caspase-3 activity than the wild-type mice (P < 0.01). The COX-2 Tg livers expressed higher levels of epidermal growth factor receptor (EGFR) than the wild-type controls; the COX-2 KO livers expressed the lowest levels of EGFR. Pretreatment with a COX-2 inhibitor (NS-398) or an EGFR inhibitor (AG1478) exacerbated Jo2-mediated liver injury and hepatocyte apoptosis. Conclusion: These findings demonstrate that COX-2 prevents Fas-induced hepatocyte apoptosis and liver failure at least in part through up-regulation of EGFR. (Hepatology 2009.)
This study shows that the cyclooxygenase‐2 (COX‐2)‐controlled prostaglandin E 2 (PGE 2 ) signaling activates Stat3 and promotes growth in human cholangiocarcinoma cells (SG231 and CCLP1). Overexpression of COX‐2 or treatment with PGE 2 or the EP 4 receptor agonist induced IL‐6 production and gp130/Stat‐3 phosphorylation and enhanced Stat‐3 reporter activity in SG231 cells. The PGE 2 ‐induced IL‐6 production was blocked by antisense suppression of EP 4 receptor but not by antisense suppression of EP 1 , EP 2 or EP3, indicating the involvement of EP 4 in IL‐6 production. Furthermore, overexpression of cPLA 2 α or COX‐2, or treatment with PGE 2 or EP 1 receptor agonist induced Stat3 phosphorylation and reporter activity in CCLP1 cells, which does not involve IL‐6 production. The observations that PGE 2 or EP 1 agonist induces the formation of Src‐Stat3 binding complex and that the Src inhibitor, PP2, blocked the EP 1 agonist‐induced Stat3 activation suggest the involvement of Src in EP 1 ‐induced Stat‐3 activation. These findings demonstrate that the COX‐2/PGE2 signaling activates Stat3 and enhances growth through two parallel mechanisms in human cholangiocarcinoma cells – the EP 4 receptor‐mediated induction of IL‐6 release (extracellular mechanism) and the EP 1 ‐receptor‐mediated activation of c‐Src (intracellular mechanism).
1. Mesencephalic astrocyte-derived neurotrophic factor (MANF), first identified in 2003 as a dopaminergic neurotrophic factor [1], is an 18-kDa endoplasmic reticulum (ER)-resident protein [2]. It i...
The progression of chronic liver disease results in severe complications. However, current treatment options remain limited. Research indicates that environmental pollutants, such as microplastics (MPs), pose a threat to the progression of chronic liver disease and represent a substantial challenge to human health. Current studies widely suggest that MPs tend to accumulate in the liver upon entering the body, potentially leading to the onset or acceleration of chronic liver disease. This article seeks to provide a comprehensive overview of the effects of MPs on chronic liver disease through various interconnected mechanisms, including cell death and autophagy, oxidative stress, inflammatory response, fibrosis, metabolic regulation, and microbial regulation. Additionally, we will briefly examine the correlation between the occurrence of chronic liver disease and microplastic exposure, as well as review the exacerbating effect of MPs on liver damage caused by other hepatotoxic substances. This study aims to serve as a reference for future research on the mechanisms of MPs in liver diseases and the development of treatment strategies for chronic liver conditions.